For the latest COVID-19 campus news and resources, visit umassmed.edu/coronavirus.

Buscar Close Search
Buscar Close Search
Page Menu

Celia Schiffer receives new NIH R21 award

Date Posted: lunes, agosto 10, 2020


Celia Schiffer, PhD, recently received a 2-year NIH R21 award from the National Institute of Allergy and Infectious Diseases.

Design of Protease Inhibitors to Target HTLV-1

Human T cell leukemia virus type 1 (HTLV-1) is the first identified human retrovirus that currently infects over 20 million people worldwide. HTLV-1 is highly carcinogenic, and infection can lead to life-threatening cancers and disabling inflammatory conditions. No inhibitors have been developed to target HTLV-1. The Schiffer laboratory will use our skills in structural biology and chemistry to design and develop robust viral protease inhibitors against HTLV-1 protease that should be less susceptible to resistance.



For more about the Schiffer Lab, please visit www.umassmed.edu/schifferlab